key: cord-0998609-sk07y7j5
authors: Hamouda Elgarhy, Lamia
title: Could patients taking isotretinoin therapy be immune against SARS‐CoV‐2?
date: 2020-05-29
journal: Dermatol Ther
DOI: 10.1111/dth.13573
sha: a8d1f74be28d32f44a2531a867560d64f9dff722
doc_id: 998609
cord_uid: sk07y7j5

nan

The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is still expanding. Angiotensin-converting enzyme 2 (ACE2) is the key host cellular protein required for SARS-CoV-2 entry. Its expression has been demonstrated in many tissues including alveolar epithelial type II cells in lungs, oral mucosa and intestine, heart, kidney, and endothelium. 1 In the skin, ACE2 immunoreactivity was detected in basal cell layer of epidermis and hair follicles, eccrine glands, blood vessels and capillaries, sebaceous glands, and its surrounding smooth muscle cells. 

Systematic cell line-based identification of drugs modifying ACE2 expression

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

Oral isotretinoin in HIV-positive women with acne: report of three cases

The use of isotretinoin in acne